抗高血压药物与勃起功能障碍

高血压及勃起功能障碍(ED)是严重威胁中老年人健康和生活质量的疾病，常用抗高血压药物对性功能有不同的影响。本文就常用抗高血压药物与ED的关系及其可能机制作一综述。     

抗高血压药物与勃起功能障碍

高血压及勃起功能障碍(ED)是严重威胁中老年人健康和生活质量的疾病,常用抗高血压药物对性功能有不同的影响.本文就常用抗高血压药物与ED的关系及其可能机制作一综述.     

阿托伐他汀对男性高血压患者勃起功能障碍的影响

目的 探讨阿托伐他汀对男性高血压患者勃起功能障碍(ED)的影响.方法 入选我院2003-07-2006-06收治的男性轻中度高血压病人838例,随机分为两组:常规降压(对照组,n=374)和常规降压 阿托伐他汀(治疗组,n=369).两组均先给予硝苯地平缓释片 依那普利进行常规降压治疗,如血压不能达标,加用氢氯噻嗪12.5 mg/d.降压达标后治疗组加用阿托伐他汀10 mg/d,对照组治疗方案不变.每4周随访1次,总共随访36周,调查分析治疗前后ED患病情况.结果 治疗组有369例,对照组有374例完成随访,治疗前两组的ED患病率为60.2% vs 60.9%(P＞0.05),差异无统计学意义.治疗后加用阿托伐他汀组的ED患病率为46.3% vs 对照组63.7%(P＜0.01),差异有非常显著意义.结论 阿托伐他汀可改善男性高血压患者勃起功能障碍.     

阿托伐他汀对男性高血压患者勃起功能障碍的影响

目的探讨阿托伐他汀对男性高血压患者勃起功能障碍(ED)的影响。方法入选我院2003-07-2006-06收治的男性轻中度高血压病人838例,随机分为两组:常规降压(对照组,n=374)和常规降压+阿托伐他汀(治疗组,n=369)。两组均先给予硝苯地平缓释片+依那普利进行常规降压治疗,如血压不能达标,加用氢氯噻嗪12.5mg/d。降压达标后治疗组加用阿托伐他汀10mg/d,对照组治疗方案不变。每4周随访1次,总共随访36周,调查分析治疗前后ED患病情况。结果治疗组有369例,对照组有374例完成随访,治疗前两组的ED患病率为60.2%vs60.9%(P>0.05),差异无统计学意义。治疗后加用阿托伐他汀组的ED患病率为46.3%vs对照组63.7%(P<0.01),差异有非常显著意义。结论阿托伐他汀可改善男性高血压患者勃起功能障碍。     

不同降压方案对男性高血压患者勃起功能的影响

目的探讨β-受体阻滞剂加利尿剂（BBs＋Diu）与钙通道拮抗剂加血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂（CCB＋ACEI／ARB）两种降压方案对男性高血压患者阴茎勃起功能的影响。方法226例确诊原发性高血压患者随机分为两组，A组78例使用BBs＋Diu降压方案，B组148例使用CCB＋ACEI／ARB降压方案，采用调查问卷方法，使用国际勃起功能（international index of erectile function，IIEF）评分5项（IIEF-5）评估阴茎勃起功能。结果A组阴茎勃起功能障碍（ED），特别是中、重度ED发病率显著高于B组（P〈0．05）。结论对中青年或性活跃的男性高血压患者，应首选CCB、ACEI、ARB，尽量少用BBs、Diu，从而减少ED的发生，提高生活质量及降压治疗的依从性。     

糖尿病勃起功能障碍的研究进展

勃起功能障碍（ED）的定义为：阴茎不能充分或维持勃起，以致不能完成满意的性生活。糖尿病（DM）是ED最重要的危险因子之一。Rendell等研究指出DM患者ED的发生率在美国高达50％。Dey等发现DM患者ED的发生率比非DM人群高3倍。2型糖尿病（T2DM）患者随着病程的延长，ED的发生率逐渐增高。吸烟史越长，吸烟的强度越大，DM患者发生ED的危险性也越高。     

男性高血压患者血压晨峰与勃起功能障碍的关系

目的:探讨男性高血压患者血压晨峰与勃起功能障碍(ED)、一氧化氮(NO)、内皮一氧化氮合酶(eNOS)的关系.方法:选择2017年1月至2020年12月在天津市第一中心医院心内科门诊就诊和住院的40～60岁男性原发性高血压患者200例为研究对象,根据24 h动态血压监测结果,收缩压晨峰值≥35 mmHg(1 mmHg=...     

不同药物联合对男性高血压患者勃起功能的影响

目的探讨不同联合降压方案对高血压男性患者勃起功能的影响。方法采用前瞻性随机、平行、对照、固定治疗方案将148名≤60岁男性高血压患者随机分为3组:A组[非洛地平5 mg/d+厄贝沙坦150 mg/d(n=49)],B组[非洛地平5 mg/d+琥珀酸美托洛尔47.5 mg/d(n=46)],C组[非洛地平5 mg/d+氢氯噻嗪12.5 mg/d(n=53)]。治疗4周若血压≥140/90 mm Hg,非洛地平剂量加倍。随访6月。采用国际男性性功能判断指标(IIEF-5)分别于治疗前、后对IIEF-5和血清睾酮、性激素结合球蛋白(SHBG)进行评定。结果治疗后3组降压达标率、有效率组间比较均无统计学差异(均P>0.05)。治疗前、后勃起功能障碍(ED)的总发生率分别为34.46%、35.81%,差异无统计学意义(P>0.05)。3组治疗前后轻、中、重度ED的发生率之间亦无统计学差异。3组治疗前后中、重度ED的IIEF-5评分比较无统计学差异,但A组可提高轻、中度ED患者的IIEF-5评分。3组血清睾酮和SHBG治疗前后比较无统计学差异。结论非洛地平缓释片联合厄贝沙坦片有利于男性高血压轻、中度ED患者性功能的改善。     

勃起功能障碍与心血管疾病

近来发现 ,勃起功能障碍与心血管疾病关系密切。在发病机制上 ,二者呈鲜明的共因和互为因果关系 ;在治疗上 ,二者之间的相互影响十分显著     

糖尿病性勃起功能障碍研究进展

勃起功能障碍是糖尿病患者常见的慢性并发症之一,糖尿病性勃起功能障碍的发病率为19.0%～ 86.3%,其发病是糖尿病性血管和神经病变、内分泌激素改变、社会和心理等多因素共同作用的结果.临床上应紧密结合糖尿病性勃起功能障碍的发病机制进行综合治疗,并遵循个体化治疗原则.严格控制血糖是基础治疗之一,同时根据情况选择不同作用机...     

降压药物与血管内皮功能不全研究进展

血管内皮有重要的生理功能,内皮功能不全与高血压密切相关,主要机制是一氧化氮生物利用度降低,不同降压药物对高血压内皮功能有不同的影响。     

Hypertension, anti-hypertensive drug therapy and erectile dysfunction in diabetes.

AIMS: Erectile dysfunction (ED) is common in diabetes and may be related to the high prevalence of hypertension and consequent anti-hypertensive drug therapy in diabetic patients. The risk factors for ED were studied with particular reference to hypertension and anti-hypertensive drugs. METHODS: We performed a retrospective case note analysis of 763 consecutive male patients (34% Type 1 diabetes, 65% Type 2 diabetes) attending an adult diabetic clinic to collect data on risk factors for ED. We specifically recorded the use of anti-hypertensive drugs. RESULTS: Two hundred and ninety-nine (39%) patients had ED. Mean age of patients with ED (61 years) was higher than those without (mean age 51 years, P < 0.001). The mean age of hypertensive patients was also significantly higher than those without. On multivariate regression analysis, age (P < 0.001), macrovascular disease (P < 0.001), sensorimotor neuropathy (P < 0.001) and HbA1c (P < 0.05) predicted ED. Neither hypertension nor any anti-hypertensive medication independently predicted ED. CONCLUSION: Our data suggest that ED in diabetic patients with hypertension may be related to the higher age and prevalence of macrovascular disease rather than hypertension or its treatment.     

顽固性高血压的降压药物治疗

顽固性高血压临床上并不少见,降压药物使用不当是主要原因之一。在排除假性顽固性高血压、纠正干扰降压药物效果的因素和治疗继发性高血压之后,大多数患者需要个体化地修正降压药物治疗方案,包括正确使用利尿剂、调整降压药物组合、在五大类降压药物(利尿剂、β受体阻滞剂、血管紧张素转换酶抑制剂、血管紧张素受体拮抗剂和钙拮抗剂)的基础上加用其他降压药物、逐一上调药物的剂量。最佳化地使用降压药物能使大多数顽固性高血压患者的血压得到有效控制。     

Associations Between Day-by-Day Variability in Blood Pressure Measured at Home and Antihypertensive Drugs: The J-HOME-Morning Study

We identified the factors associated with home blood pressure (BP) variability in 1933 patients treated with hypertensive drugs (mean age, 67 years; women, 55%). Multivariate regression analysis showed that female gender, advanced age, home BP value, and home heart rate variability were positively associated with home BP variability, whereas home heart rate, body mass index, and duration of antihypertensive treatment were negatively associated with home BP variability. Moreover, not being medicated with amlodipine and being medicated with angiotensin II receptor blockers were associated with increased home systolic BP variability only among patients who were treated for less than 12 months.     

Associations Between Visit-to-visit Variability in Blood Pressure Measured in the Office and Antihypertensive Drugs: The J-HOME-Morning Study

The factors associated with visit-to-visit variability in blood pressure (BP) measured in the office between the two visits were identified in 1379 treated hypertensive patients (mean age, 66.1 ± 11.0 y; women, 53.8%). Multivariate regression analysis showed that office BP and visit-to-visit heart rate variability were positively associated with visit-to-visit BP variability, whereas body mass index, duration of antihypertensive medication, and taking amlodipine were negatively associated with visit-to-visit BP variability. Further prospective studies are required to clarify the causal relationships between these factors and visit-to-visit BP variability among treated hypertensive patients.     

Blood Pressure Control in Patients with Hypertension: a Community-Based Study

The objective of own study was to investigate the quality of hypertension management in a rural Chinese population. A prospective cross-sectional study was conducted in 922 hypertensive patients in a regional community in southern China. The average systolic (SBP) and diastolic blood pressure (DBP) was 167.8 ± 22.5 mmHg and 94.3 ± 14.2 mmHg respectively. A total of 823 patients (89.3%) patients had a SBP of greater than or equal to 140 mmHg, and 596 (64.6%) had a DBP of greater than or equal to 90 mmHg. Fully 568 patients (69.7%) were treated with one or two antihypertensive drugs, mostly with calcium channel blockers. In patients treated with antihypertensive drugs, the average SBP and DBP were 170.3 ± 23.1 mmHg and 96.2 ± 14.8 mmHg, respectively. Blood pressure was poorly controlled in these hypertensive patients. Further studies are required to identify the barriers to the effective management of uncontrolled hypertension in a rural setting.     

Prestroke Antihypertensive Therapy: Effect on the Outcome

About 70% of stroke patients have a history of hypertension. Patients with hypertension prior to stroke onset have higher blood pressure in the acute phase of stroke than non-hypertensive individuals. High blood pressure in the acute stroke adversely affects outcome. We analyzed 30-days outcome in 1306 hypertensive patients with ischemic stroke, of which 1069 (81.8%) received antihypertensive treatment before stroke onset. Multivariate logistic regression revealed that prestroke use of antihypertensives is an independent predictor of better stroke outcome, in terms of dependency and death or dependency. We conclude that increased efforts toward optimizing hypertension diagnostics and control are needed.     

人群三年降压治疗的疗效观察

目的 对比观察4种降压药物联合方案长期治疗原发性高血压病(EH)的疗效。方法 选择EHⅡ期、Ⅲ期患者892例，按入选顺序分为4组：A组为尼群地平加卡托普利，B组为尼群地平加氨酰心安，C组为硝苯地平加卡托警利加双氢克尿噻，D组为复方降压片，各种原因退出以上4组的为E组；在治疗前后检测血压、血尿常规、肾功髓、24小时尿蛋白、眼底检查及心脏B超。部分患者检测了神经内分泌因子。结果 在治疗后1、3年，5组患者动辣血压均较治疗前明显下降；LVMI和A／E比值均下降，CO和LVEF无变化，血BUN、Cr无变化；各组间无统计学差异。其中A、B、C组的24小时尿蛋白、血尿酸明显下降，眼底情况明显改善，而D、E组则反之；心脑血管疾病死亡例数D、E组明显高于A、B、C组。结论 坚持长期降压治疗可明显减少高危患者的病死率和并发症，并保护其靶器官受损，制定合、理、安全、有效、经济的降压方案对EH患者的管理率、服药率、控制率都有着重要的临床价值和社会意义。